Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells
Fig 1
Effect of nanoparticle curcumin on the development of DSS colitis.
BALB/cAJcl mice were treated with nanoparticle curcumin (Theracurmin) for 7 days prior to the start of 3% DSS treatment. The mice were sacrificed on day 18. (A) Body weight. (B) Disease activity index. (C) Representative photographs of the colon. (D) Colonic weight/length on day 18. The data are expressed as means ± SEM (n = 6 mice/group). The data are representative of four independent experiments. Values not sharing a letter are significantly different (P<0.05).